Login
Alkermes plc. logo

Alkermes plc.

alkermes.com

What Do They Do?

Sells medicines for dependence, mental health conditions and narcolepsy to pharmaceutical wholesalers, pharmacies and treatment providers.

How Do They Make Money?

Alkermes earns product-sale revenue when customers receive its medicines. It earns manufacturing revenue when products are fully made and royalties when licensees sell products using its technologies or license its product.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Product sales, net
Sold outright

80%
FY2022: 70%
Manufacturing and royalty revenues
Mix

20%
FY2022: 30%

Who Are Their Customers?

Alkermes sells its U.S. medicines mainly to pharmaceutical wholesalers, specialty distributors and pharmacies; VIVITROL also goes to treatment providers. Licensees commercialize products covered by their agreements.

Do Revenues Turn Into Profits?

Yes. It kept 16 cents of every revenue dollar as net income in FY2025 and turned 33 cents into free cash flow.

Operating income, FY2025
17% of revenue
▼ −40% vs FY2024 ($420.6M, 27%)
Net income, FY2025
16% of revenue
▼ −34% vs FY2024 ($367.1M, 24%)
Free cash flow, FY2025
33% of revenue
▲ +18% vs FY2024 ($405.6M, 26%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +22%
vs $394.2M in Q3 FY2025
Net income
▼ −80%
vs $82.8M in Q3 FY2025
Product sales, net share of revenue vs 80.5% in Q3 FY2025
  • Nov 6, 2026 Settles LYBALVI patent suit and grants Teva a limited sales license The license permits U.S. sales beginning November 12, 2039, or May 12, 2040 if Alkermes obtains pediatric exclusivity, subject to earlier-entry terms.

Growing. Revenue grew 26% in 4 years, from $1.2B in FY2021 to $1.5B in FY2025, about 6% a year.

Added narcolepsy treatment The latest report adds LUMRYZ, a narcolepsy medicine, to the proprietary commercial portfolio; the older report described proprietary products focused on dependence, schizophrenia and bipolar I disorder.

Revenue over time
Product sales, net Manufacturing and royalty revenues License revenue Research and development revenue
$2B$1B$0

Who Do They Compete With?

Competes with Teva, Lilly, Luye Pharma Group, MedinCell, Lupin, Amneal Pharmaceuticals, Johnson & Johnson, Abbvie, Bristol-Myers Squibb, Indivior, BioDelivery Sciences, Orexo US, Braeburn, Genentech, Bayer HealthCare Pharmaceuticals, EMD Serono, Novartis, Sanofi-Aventis, Axsome Therapeutics, and Harmony Biosciences Holdings

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support